Goldman Sachs Group Inc Anebulo Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 47,954 shares of ANEB stock, worth $51,790. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,954
Previous 47,954
-0.0%
Holding current value
$51,790
Previous $62,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ANEB
# of Institutions
19Shares Held
22.6MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA15.5MShares$16.7 Million18.74% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.04MShares$3.28 Million0.18% of portfolio
-
Mangrove Partners New York, NY2.53MShares$2.73 Million0.52% of portfolio
-
Morgan Stanley New York, NY399KShares$431,1560.0% of portfolio
-
Lvw Advisors, LLC350KShares$377,5860.06% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $27.7M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...